Bart P H Pouls1,2, Lars E Kristensen3, Marianne Petersson4, B J F van den Bemt1,2, Luca Ballerini5, Richard Bruggraber6, Henrik Karlen7, Irina Mountian8, Etienne van Bracht9, Susanne Wiegratz10, Tanja S Jørgensen3. 1. Sint Maartenskliniek, Nijmegen, Netherlands. 2. Radboud University Medical Center, Nijmegen, The Netherlands. 3. The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark. 4. Department of Molecular and Clinical Medicine, Linköping University, Linköping, Sweden. 5. UCB Pharma, Bulle, Switzerland. 6. UCB Pharma, Slough, UK. 7. UCB Pharma, Stockholm, Sweden. 8. UCB Pharma, Brussels, Belgium. 9. UCB Pharma, Breda, The Netherlands. 10. UCB Pharma, Monheim, Germany.
Abstract
Background: Anti-tumor necrosis factor (anti-TNF) adherence is suboptimal. ava®, a reusable electromechanical self-injection device (e-Device) developed for certolizumab pegol (CZP) administration, aims to overcome some barriers to increase adherence. This study evaluates patient experience of the e-Device and its training materials and determines patient device preference. Methods: CZP-treated patients were recruited from the Netherlands, Denmark and Sweden. Patients completed a pre-injection Assessment of Self-Injection (ASI) questionnaire investigating self-injection perception. After training, patients administered 3 consecutive self-injections using the e-Device, patient experience of each was assessed using the post-injection ASI. An additional questionnaire evaluated training materials. After Injection 3, patients indicated their preference: the e-Device or their previous device. Results: 59 patients participated; most rated the e-Device highly for satisfaction, self-confidence and ease of use. The (negative) feelings and pain and skin reactions domains had low ratings. Post-injection ASI domain scores were similar following each of the 3 e-Device injections. Training materials were rated highly (video: 8.4/10; step-by-step guide: 8.4/10). 57.1% (32/56) patients preferred the e-Device over their previous self-injection device.Conclusions: Patients were satisfied with the e-Device and most preferred it over other self-injection devices. By improving patient experience, the e-Device may help increase medication adherence.
Background: Anti-tumornecrosis factor (anti-TNF) adherence is suboptimal. ava®, a reusable electromechanical self-injection device (e-Device) developed for certolizumab pegol (CZP) administration, aims to overcome some barriers to increase adherence. This study evaluates patient experience of the e-Device and its training materials and determines patient device preference. Methods:CZP-treated patients were recruited from the Netherlands, Denmark and Sweden. Patients completed a pre-injection Assessment of Self-Injection (ASI) questionnaire investigating self-injection perception. After training, patients administered 3 consecutive self-injections using the e-Device, patient experience of each was assessed using the post-injection ASI. An additional questionnaire evaluated training materials. After Injection 3, patients indicated their preference: the e-Device or their previous device. Results: 59 patients participated; most rated the e-Device highly for satisfaction, self-confidence and ease of use. The (negative) feelings and pain and skin reactions domains had low ratings. Post-injection ASI domain scores were similar following each of the 3 e-Device injections. Training materials were rated highly (video: 8.4/10; step-by-step guide: 8.4/10). 57.1% (32/56) patients preferred the e-Device over their previous self-injection device.Conclusions: Patients were satisfied with the e-Device and most preferred it over other self-injection devices. By improving patient experience, the e-Device may help increase medication adherence.
Authors: Farrah Pompilus; Anna Ciesluk; Sara Strzok; Valerie Ciaravino; Kristina Harris; Boglarka Szegvari; Irina Mountian; Sophie Cleanthous; Juliette Meunier Journal: Health Qual Life Outcomes Date: 2020-11-04 Impact factor: 3.186